
Nov 20, 2026 · 22 min
Listen from 21:40
Listen at 21:40
FDA leadership falters as China biotech reshapes drug competition
422: FDA's search for a new leader, and China's largest drugmakers
The episode connects a stalled FDA leadership transition with rising scrutiny of Chinese biotech, cross-border investment, and trial evidence.
- 1Heidi Overton’s nomination collapsed after senators raised concerns about vaccines, flavored vapes, and abortion medication access.
- 2China’s biotech leaders pursue sharply different models as U.S. policymakers debate investment restrictions and partnerships.
- 3The FDA rejected ibanesimab after questioning its survival evidence and the geographic diversity of the supporting trial.
Don't miss
Margaret Manto explains how opposition over vaccines, flavored vapes, and abortion medication access helped derail Heidi Overton’s nomination.
The brief
The FDA enters another period of uncertainty after the Trump administration withdrew Heidi Overton’s nomination, despite claims she had enough support to advance.
STAT’s ranking of China’s largest drugmakers shows a sector with distinct strategies, from global commercialization to in-house research and frequent licensing.
A proposed Treasury rule could restrict U.S. investment in Chinese biotech, while exemptions for conventional licensing deals remain part of the debate.
The FDA rejected Summit Therapeutics’ ibanesimab, developed with Akeso, citing no overall-survival benefit and concerns that trial events were concentrated among Chinese patients.
Guest Margaret Manto details the opposition campaign against Overton and the possible permanent or acting successors as Republicans face a narrowing confirmation window.
What was said on this episode
13 statements · 4 positive · 3 negative · 3 mixed · 3 neutral
Chinese biotech consists of competing firms with diverse strategies and histories.
“the Chinese biotech industry is described as a monolith. But that, of course, is not... how it is. It couldn't be further from the truth. It is rather a bunch of competing firms with differing strategies, differing histories, differing approaches to making medicines for human beings.”
Listen at 2:18
China’s biotech and scientific rise is highly important to global health’s future.
“The remarkable ascendance of not just the Chinese biotech industry, but the Chinese scientific apparatus, whether it's in academia or industry, is massively important to everything we cover and to the future of global health.”
Listen at 2:57
B1 Medicines ranks first in the China biotech powerhouse index.
“It is B1 Medicines, formerly Baijin, I believe is how it was pronounced, which is an interesting firm in that they were designed to straddle East and West.”
Listen at 4:28
B1 Medicines and Hungry Pharmaceuticals each have approximately $50 billion market capitalizations.
“each has a market cap of about $50 billion.”
Listen at 5:12
The outcomes of B1 Medicines’ and Hungry Pharmaceuticals’ strategies remain uncertain.
“we'll see which of those strategies plays out.”
Listen at 5:28
The proposed Treasury rule appears to exempt conventional drug-licensing deals with Chinese companies.
“the proposed rule as written appears to carve out the kind of deals we seem to see once a week where the likes of Pfizer or Bristol-Myers Squibb or Merck licenses a medicine from a Chinese company.”
Listen at 7:17
The proposed rule would harm America’s venture-capital community by restricting complex China biotech deals.
“what would be affected is something that would be much more deleterious to america's venture capital community which is more complicated deals”
Listen at 7:31
The proposed Treasury rule may change substantially or never be implemented.
“American firms taking equity in Chinese firms. This will all get ironed out. And as with any proposed rule change, if implemented, it could be quite different. It could also never be implemented.”
Listen at 7:56
Ibanesimab improved progression-free survival but not overall survival in the lung-cancer study.
“The study showed a benefit on progression-free survival, which is, you know, delaying the time of tumor progression. But what it did not do, importantly, was it did not prolong survival in these patients.”
Listen at 10:23
The FDA rejected Summit’s ibanesimab application after warning that survival benefit was needed.
“the FDA told Summit that without a survival benefit, you shouldn't file this drug for approval. Summit did that anyway, didn't listen to the FDA, filed the drug, and lo and behold, we found out over the weekend that the FDA rejected it.”
Listen at 10:35
The FDA has consistently required geographically diverse data for cancer-drug approvals.
“the FDA has been pretty, you know, they've been sticklers on this. This is a... policy that dates back to Richard Pazter when he was running the FDA's cancer drug division”
Listen at 11:43
Margaret Manto thinks Overton may have lacked Senate support for confirmation.
“it is quite possible that Overton, in fact, did not have the votes and she did not have the required support from a couple holdouts.”
Listen at 16:58
- Margaret Mantoon FDA acting commissioner tenureNeutral20:20
FDA acting commissioners can serve for 210 days before replacement or departure.
“acting commissioners can serve for 210 days.”
Listen at 20:20
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.